REFRACTORY MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough leukemia in patients with RUNX1 mutation
Disease control TerminatedThis study tested two drugs, omacetaxine and venetoclax, in 24 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to treatment. All participants had a specific genetic change called RUNX1. The goal was to find the best dose and see if t…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
New drug combo tested for tough leukemia cases
Disease control TerminatedThis early-stage study tested two chemotherapy drugs, pevonedistat and belinostat, in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior treatment. The main goal was to find the safest dose and understand side effects. The s…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
Promising combo for tough blood cancer hits snag: trial halted
Disease control TerminatedThis study tested two drugs, venetoclax and azacitidine, together in people with a serious type of bone marrow cancer called high-risk myelodysplastic syndrome (MDS). The goal was to find the best dose and see if the combo could shrink or control the cancer. The trial included 51…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC